As for TP53, the combined mutated status of TP53 and ATM was previously linked to clinical response to chemotherapies,55 Whereas TP53 mutants induce HER2 overexpression in cancer cells,56 which may constitute an anticancer resistance mechanism.57 The gene discussed is ERBB2; the disease is cancer.